Nanoengineering Approaches to Fight Multidrug-Resistant Bacteria

Seena, Sahadevan; Rai, Akhilesh

doi:10.1007/978-981-19-9167-7_9

Cited by 3 publications

(2 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One new field of study involves the modulation of bacterial antimicrobial efflux pump alteration in expression by nanoparticles [180,181]. We anticipate that this area shows further promise toward generating new treatment strategies against potentially untreatable infections caused by multidrug-resistant pathogens [182]. Surprisingly, although many studies show inhibition of multidrug resistance in transporters of the MFS [9,23,92,93,183], few, if any, of these modulatory agents have reached clinical trials, suggesting that a focus on this area of infectious disease investigation is lacking.…”

Section: Future Directionsmentioning

confidence: 99%

Inhibition of Multidrug Efflux Pumps Belonging to the Major Facilitator Superfamily in Bacterial Pathogens

et al. 2023

View full text Add to dashboard Cite

Bacterial pathogens resistant to multiple structurally distinct antimicrobial agents are causative agents of infectious disease, and they thus constitute a serious concern for public health. Of the various bacterial mechanisms for antimicrobial resistance, active efflux is a well-known system that extrudes clinically relevant antimicrobial agents, rendering specific pathogens recalcitrant to the growth-inhibitory effects of multiple drugs. In particular, multidrug efflux pump members of the major facilitator superfamily constitute central resistance systems in bacterial pathogens. This review article addresses the recent efforts to modulate these antimicrobial efflux transporters from a molecular perspective. Such investigations can potentially restore the clinical efficacy of infectious disease chemotherapy.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Inhibition of Multidrug Efflux Pumps Belonging to the Major Facilitator Superfamily in Bacterial Pathogens

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Barring antibiotics, metal compounds were largely in use and practice before the 1920s, after which antibiotics took over [18][19][20]. The potential of metals to conveniently restrict biofilm production make them the best possible alternative in present times [21,22].…”

mentioning

confidence: 99%

Combating Microbial Infections Using Metal-Based Nanoparticles as Potential Therapeutic Alternatives

Kaur

Kaur²,

Alyami

et al. 2023

Antibiotics

View full text Add to dashboard Cite

The nature of microorganisms and the efficiency of antimicrobials have witnessed a huge co-dependent change in their dynamics over the last few decades. On the other side, metals and metallic compounds have gained popularity owing to their effectiveness against various microbial strains. A structured search of both research and review papers was conducted via different electronic databases, such as PubMed, Bentham, Springer, and Science Direct, among others, for the present review. Along with these, marketed products, patents, and Clinicaltrials.gov were also referred to for our review. Different microbes such as bacteria, fungi, etc., and their diverse species and strains have been reviewed and found to be sensitive to metal-carrying formulations. The products are observed to restrict growth, multiplication, and biofilm formation effectively and adequately. Silver has an apt use in this area of treatment and recovery, and other metals like copper, gold, iron, and gallium have also been observed to generate antimicrobial activity. The present review identified membrane disruption, oxidative stress, and interaction with proteins and enzymes to be the primary microbicidal processes. Elaborating the action, nanoparticles and nanosystems are shown to work in our favor in well excelled and rational ways.

show abstract

Strategies and Innovations in the Battle Against Antibiotic Resistance

Bhattacharya

2024

Advances in Medical Diagnosis, Treatment, and Care

View full text Add to dashboard Cite

Antimicrobial resistance (AMR) poses a severe global health crisis, claiming over 1.27 million lives worldwide in 2019. In the U.S., more than 2.8 million cases of resistant infections annually result in 35,000 deaths. This chapter delves into the complexities of multi-drug-resistant pathogens, exploring historical instances of resistance and advocating for innovative solutions. It explores alternatives like peptides, gene editing, and unconventional therapies, while addressing challenges in research and the decline of new antibiotic development. Uniquely interdisciplinary, the chapter integrates insights from literature, healthcare reports, and pharmaceutical trends. Meticulously organized, it navigates through challenges and promising innovations, concluding with a call for global action to combat the escalating threat of antibiotic resistance. This knowledge, drawn from literature, case studies, and industry trends, has the potential to significantly advance therapies, safeguard public health, and shape the future of medicine.

show abstract

Nanoengineering Approaches to Fight Multidrug-Resistant Bacteria

Cited by 3 publications

References 112 publications

Inhibition of Multidrug Efflux Pumps Belonging to the Major Facilitator Superfamily in Bacterial Pathogens

Inhibition of Multidrug Efflux Pumps Belonging to the Major Facilitator Superfamily in Bacterial Pathogens

Combating Microbial Infections Using Metal-Based Nanoparticles as Potential Therapeutic Alternatives

Strategies and Innovations in the Battle Against Antibiotic Resistance

Contact Info

Product

Resources

About